Here in CT our proposed 2018 budget includes expanding the insurance fund for immunizations by $11 million. $9.5 million is slated for the purchase of HPV vaccines.
It is our understanding that this fund is paid through an insurance assessment fee and passed on to our premiums, which can be expected to rise with this additional expense.
There are many issues with buying and promoting this controversial vaccine.
As of March 2017, there were a total of 50,463 vaccine reaction reports made to the federal Vaccine Adverse Events Reporting System (VAERS) associated with Gardasil, HPV vaccines. Reports associated with Gardasil and Cervarix, (GlaxoSmithKline) shots include unexplained collapse, seizures, muscle pain and weakness, disabling fatigue, paralysis, brain inflammation, rheumatoid arthritis, lupus, blood clots, multiple sclerosis, optic neuritis, spontaneous abortions, strokes, heart and other serious health problems including 318 deaths.1 (VAERS reporting is voluntary, therefore it estimated that these numbers represent less than 10% of the actual total adverse events.)2
Since the fast tracked licensure of Gardasil in 2006, there have been about 213 VAERS reports involving amenorrhea, POF or premature menopause. Long-term ovarian function was not assessed in either the original rat safety studies or in the human vaccine trials.” 3 It is not known whether Gardasil 4 or Cervarix 5 can cause infertility, cancer or damage genes. The American College of Pediatrics released a statement regarding this concern.
Not only have several countries removed HPV from their recommended schedule, but France, Spain, India, and Japan have each led criminal charges against HPV vaccine manufacturers for fraud, safety, and providing misleading information. 6
With over 100 strains, HPV is the most common STD in the US. HPV infection is experienced by the majority of sexually active women and men without symptoms and is naturally cleared from the body within two years by more than 90% of those who become infected.7
Since most cervical pre-cancers develop slowly, cancer can usually be prevented with regular screenings. With the advent of regular pap screening in the 1960’s, cervical cancer has declined more than 70% in the U.S. 8 Most women diagnosed with cervical cancer have never or not recently been screened. 9
Protecting against only up to 9 of the 100 total strains of HPV (at least 16 of which are suspected oncogenic)10, claims that the HPV vaccine provides adequate protection from HPV infection and cervical cancer are dangerously inflated and misleading. This misinformation can lead patients to a false sense of security following vaccination and to therefore neglect the most proven prevention method of early screening from an OB/GYN, thus increasing the patient’s risk of developing cervical cancer.
The FDA allowed Merck to use a potentially reactive aluminum containing placebo as a control for most Gardasil trial participants, rather than a non-reactive saline solution placebo.11 GSK used Hepatitis A vaccines and other childhood vaccines that can cause serious reactions as “placebos” during Cervarix clinical trials.12
The Department of Health and Human Services receives royalty payments on Gardasil and Cervarix. This conflict of interest in related DHHS agencies cannot be ignored. 13
CT pathologist, Dr. Sin Hang Lee was an expert witness in compensated HPV vaccine injury case Gomez Vs. USDOH. His research in this case led to an understanding of the injury vector and he subsequently wrote and submitted a very compelling comment 14 on the NCI Shiffman study used to inform HPV vaccine policy. Dr. Lee’s comments were wiped from pubmed, but remain on pub peer. To date, no response has been issued.He has an open letter of complaint 15 to the World Health Organization director Margaret Chan for suppression of injury information by key policymakers at CDC and other agencies and for misleading global vaccination policy makers at the expense of public health interests.
Please visit SANEVAX.org for more information